Ngwe Phyo1, Wegin Tang2, Venu Kavarthapu1,3. 1. Department of Trauma & Orthopaedics, King's College Hospital, London, UK. 2. Diabetic Foot Clinic, King's College Hospital, London, UK. 3. University of Southern Denmark, Denmark.
Abstract
BACKGROUND: Heel ulcers in patients with peripheral neuropathy and diabetes pose a significant challenge to treating physicians. Infection spreading to the os calcis is associated with a poor prognosis. There is no consensus on which method of surgical treatments results in better outcomes. The aim of this study was to assess patients' survival, rate of ulcer healing following surgical treatment, along with limb salvage rate, time taken for healing, ulcer recurrence and patients' functional outcome after healing. METHODS: We studied 29 patients (20 men, 9 women) presenting with diabetic neuropathic heel ulcers (30 feet) and no critical limb ischemia, were managed surgically in our unit and followed-up for a minimum of 12 months. We assessed their clinical and functional outcomes within a mean follow-up period of 28 months (12-83). RESULTS: 11 out of 29 patients died (38%) with mean duration of post op survival being 31months (range 4-70). 14 ulcers (50%) healed fully within a mean of 360 days (131-1676). Limb salvage was achieved in 29 feet (97%). Only 5 out of 17 patients with diabetic nephropathy (p value 0.016) and 9 out of 24 ulcers with calcaneal osteomyelitis (p value 0.044) achieved full ulcer healing. Ulcer recurrence rate was 36% (5/14) within 12 months of achieving ulcer healing. Six patients were able to return to independent walking in surgical shoes while 11 patients were mobilising using either a crutch or frame. CONCLUSION: While excellent limb salvage can be anticipated from the outcome of surgically managed infected heel ulcers in patients with diabetes, complete healing can still be slow and unpredictable. Significant medical co-morbidities in these patients make them vulnerable to medium-term post-operative complication and survival. Crown
BACKGROUND: Heel ulcers in patients with peripheral neuropathy and diabetes pose a significant challenge to treating physicians. Infection spreading to the os calcis is associated with a poor prognosis. There is no consensus on which method of surgical treatments results in better outcomes. The aim of this study was to assess patients' survival, rate of ulcer healing following surgical treatment, along with limb salvage rate, time taken for healing, ulcer recurrence and patients' functional outcome after healing. METHODS: We studied 29 patients (20 men, 9 women) presenting with diabetic neuropathic heel ulcers (30 feet) and no critical limb ischemia, were managed surgically in our unit and followed-up for a minimum of 12 months. We assessed their clinical and functional outcomes within a mean follow-up period of 28 months (12-83). RESULTS: 11 out of 29 patients died (38%) with mean duration of post op survival being 31months (range 4-70). 14 ulcers (50%) healed fully within a mean of 360 days (131-1676). Limb salvage was achieved in 29 feet (97%). Only 5 out of 17 patients with diabetic nephropathy (p value 0.016) and 9 out of 24 ulcers with calcaneal osteomyelitis (p value 0.044) achieved full ulcer healing. Ulcer recurrence rate was 36% (5/14) within 12 months of achieving ulcer healing. Six patients were able to return to independent walking in surgical shoes while 11 patients were mobilising using either a crutch or frame. CONCLUSION: While excellent limb salvage can be anticipated from the outcome of surgically managed infected heel ulcers in patients with diabetes, complete healing can still be slow and unpredictable. Significant medical co-morbidities in these patients make them vulnerable to medium-term post-operative complication and survival. Crown
Authors: Luca Dalla Paola; Anna Carone; Giulio Boscarino; Giuseppe Scavone; Lucian Vasilache Journal: Int J Low Extrem Wounds Date: 2016-09-30 Impact factor: 2.057
Authors: Éric Senneville; Benjamin A Lipsky; Zulfiqarali G Abbas; Javier Aragón-Sánchez; Mathew Diggle; John M Embil; Shigeo Kono; Lawrence A Lavery; Matthew Malone; Suzanne A van Asten; Vilma Urbančič-Rovan; Edgar J G Peters Journal: Diabetes Metab Res Rev Date: 2020-03 Impact factor: 4.876
Authors: Kristy M Pickwell; Volkert D Siersma; Marleen Kars; Per E Holstein; Nicolaas C Schaper Journal: Diabetes Metab Res Rev Date: 2013-07 Impact factor: 4.876